tiprankstipranks
Bayer AG (BAYRY)
OTHER OTC:BAYRY
Want to see BAYRY full AI Analyst Report?

Bayer (BAYRY) Price & Analysis

2,098 Followers

BAYRY Stock Chart & Stats

$11.02
-$0.08(-1.46%)
At close: 4:00 PM EST
$11.02
-$0.08(-1.46%)

Bulls Say, Bears Say

Bulls Say
Operational Cost Savings & DSO ProgramThe DSO program has produced material, recurring cost reductions and organizational flattening, improving structural operating leverage and speed-to-market. Sustained €2bn savings reduce break-even risk, support margins and free cash flow resilience even as revenue pressures persist.
Pharmaceutical Launch MomentumMultiple high-growth launches materially diversify Pharma revenue mix and indicate durable commercial execution. Strong early adoption for Nubeqa/Kerendia supports sustained mid-term revenue and margin expansion in Pharma, reducing reliance on legacy franchises facing decline.
Large Asset Base And Improved 2025 Debt PositionScale of assets and meaningful equity provide strategic financial flexibility. Recent deleveraging and below-€30bn net debt at 2025 year-end improves ability to fund R&D, launches and litigation settlements without immediate structural impairment to operations.
Bears Say
Large Litigation Liabilities & Expected PayoutsSubstantial litigation provisions create a persistent cash and balance-sheet overhang. Known liabilities compress available capital, raise funding and ratings risk, and can crowd out investment or force financings that dilute strategic optionality over multiple years.
Multi-year Revenue Decline & Sustained Net LossesA multi-year top-line contraction combined with repeated net losses erodes return on capital and equity. Sustained revenue weakness reduces scale benefits, pressures margins and makes long-term recovery dependent on successful launches and structural cost reductions.
Weakening Cash Generation And Projected 2026 Negative FCFDeclining operating and free cash flow reduce financial flexibility and increase reliance on external funding. Projected negative FCF in 2026 tied to litigation payouts will likely force higher net debt, constrain capex/R&D pacing and elevate refinancing and ratings vulnerability.

Bayer News

BAYRY FAQ

What was Bayer AG’s price range in the past 12 months?
Bayer AG lowest stock price was $6.21 and its highest was $14.56 in the past 12 months.
    What is Bayer AG’s market cap?
    Bayer AG’s market cap is $43.85B.
      When is Bayer AG’s upcoming earnings report date?
      Bayer AG’s upcoming earnings report date is May 12, 2026 which is in 11 days.
        How were Bayer AG’s earnings last quarter?
        Bayer AG released its earnings results on Mar 04, 2026. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.066.
          Is Bayer AG overvalued?
          According to Wall Street analysts Bayer AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Bayer AG pay dividends?
            Bayer AG pays a Annually dividend of $0.031 which represents an annual dividend yield of 0.29%. See more information on Bayer AG dividends here
              What is Bayer AG’s EPS estimate?
              Bayer AG’s EPS estimate is 0.68.
                How many shares outstanding does Bayer AG have?
                Bayer AG has 3,929,696,000 shares outstanding.
                  What happened to Bayer AG’s price movement after its last earnings report?
                  Bayer AG reported an EPS of $0.18 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went down -1.826%.
                    Which hedge fund is a major shareholder of Bayer AG?
                    Currently, no hedge funds are holding shares in BAYRY
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Bayer AG

                      Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

                      Bayer (BAYRY) Earnings & Revenues

                      BAYRY Earnings Call

                      Q4 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Neutral
                      The call balanced clear operational progress—delivery of raised guidance, improved launch momentum in Pharma, meaningful DSO-driven cost savings, and a reduced net financial debt position in 2025—against substantial legal and cashflow headwinds. Management articulated tangible growth drivers across Crop Science, Pharma and Consumer Health and concrete cost-savings milestones, but also disclosed large litigation provisions (EUR 11.8 billion liabilities), expected negative free cash flow in 2026 due to ~EUR 5 billion litigation-related payouts, projected net debt increase and significant product declines (notably Xarelto and Eylea). Given the mix of strong operational execution and material financial/legal risks that will weigh on near-term cash flow and balance-sheet metrics, the tone of the call is cautiously constructive but realistic about the challenges ahead.View all BAYRY earnings summaries
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Bristol-Myers Squibb
                      Gilead Sciences
                      GlaxoSmithKline
                      Pfizer
                      Sanofi

                      Ownership Overview

                      0.17%<0.01%99.70%
                      Insiders
                      <0.01% Other Institutional Investors
                      99.70% Public Companies and
                      Individual Investors

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks